STAT

•

Stanica • Relácie: 2

Obchod

Obchod

Týždenne
Správy

Správy

Dvojtýždenne

12. 2.

388: The FDA's refusal to review Moderna's mRNA flu vaccine

We’re devoting our entire episode this week to one controversial and impactful topic: the FDA’s decision to block the review of Moderna’s mRNA flu shot. STAT was the first to report that Vinay Prasad, the agency’s top regulator of vaccines, overruled the head of the FDA’s vaccine office and other staffers in making that decision. Prasad’s unilateral action has renewed concerns about the FDA’s regulatory posture under the Trump administration. To help us dig deeply into this important story and its ramifications, we bring on STAT reporters Lizzy Lawrence and Matthew Herper. We also chat with Moderna President Stephen Hoge and former FDA official Jesse Goodman.

12. 2.

•

51 min
19. 2.

389: Hims' Super Bowl fallout, and the FDA reverses course

Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening behind-the-scenes with Moderna and the Food and Drug Administration? We discuss all that on this week's episode of "The Readout LOUD." STAT's Katie Palmer joins Adam, Elaine, and Allison to discuss the Hims GLP-1 pill fallout. The hosts also discuss the latest on Moderna's influenza vaccine application and Compass Pathways' depression psychedelic data.

19. 2.

•

34 min
5. 2.

387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, which triggered some co-host squabbling. Adam Feuerstein is all Patriots, Elaine Chen is Team Seahawks, while Allison DeAngelis, raised in Seattle but now a Boston denizen, struggles with dual loyalties. Our special guest this week is STAT reporter Jason Mast. And if you get a chance, wish Adam a happy birthday.

5. 2.

•

28 min
18. 12. 2025

382: Biotech's year in review

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.We also chat about Adam's picks for best and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk's direct-to-consumer offerings may be contributing to employers' decisions to drop coverage of weight loss drugs.

18. 12. 2025

•

34 min
8. 1.

383: JPM to bring more deals and happy CEOs

What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. We bring on former co-host Damian Garde, who’s now a reporter at large at STAT, to preview the upcoming J.P. Morgan Healthcare Conference. We also discuss the approval of Novo Nordisk’s Wegovy pill, the federal government’s move to slash the number of recommended pediatric immunizations, and the resurgence of M&A deals.

8. 1.

•

34 min
04. 12. 2025

380: A new top drug regulator and the future of psychedelics

On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news. Our special guest this week is David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics and the co-founder of Delix Therapeutics, a startup that is developing a new class of neuropsychiatric medicines that are similar to psychedelics in that they can exert strong and rapid therapeutic benefits, but without the hallucinogenic effects.

04. 12. 2025

•

33 min
29. 1.

386: The high stakes for Huntington's patients

Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington's disease, and the outcome could be potentially devastating for patients. That's what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator's changing perspective on UniQure's trial affects patients, and patients' attempts to petition the agency to reverse course. Adam, Elaine, and Allison also chat about the latest news in the life sciences, including the new slate of drug prices negotiated by Medicare, a rise in pharmaceutical industry lobbying, and a halt on another gene therapy trial.

29. 1.

•

42 min
11. 12. 2025

381: The future of American science and a dispatch from ASH

How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health? First, we discuss all things ASH, particularly Tern’s chronic myeloid leukemia data, Johnson & Johnson’s multiple myeloma data, and Fulcrum Therapeutics’ pill for sickle cell disease. We also get into the latest news in — what else? — obesity drugs. Then, STAT reporters Megan Molteni and Anil Oza join for a conversation on the new series “American Science, Shattered,” which details this fissure and what it means for the future of the country’s scientific institutions.

11. 12. 2025

•

33 min
29. 10. 2025

A ‘devil’s choice’ on vaccines and pandemic preparedness

Vaccine hesitancy isn’t new, Seth Berkley points out. “The first vaccine was smallpox vaccine,” he said on this week’s episode of the “First Opinion Podcast,” “and right after they were first used, there were wood cuttings of people with cows’ horns growing out of their heads because the virus was isolated from cows.” Berkley is the former head of Gavi, the Vaccine Alliance, a co-founder of COVAX, and author of the new book “Fair Doses: An Insider’s Story of the Pandemic and the Global Fight for Vaccine Equity.” On this episode of the podcast, we discussed what went right and wrong with the response to Covid — and preparing for the next pandemic.

29. 10. 2025

•

30 min
06. 04. 2022

Episode 49: Should gender dysphoria be a required stop en route to gender euphoria?

For trans people who want to receive gender-affirming medical care such as hormone treatments or surgery, one requirement is often a diagnosis of "gender dysphoria," which the Diagnostic and Statistical Manual of Mental Disorders defines as deep psychological distress around one's gender. But not all trans people experience gender dysphoria. Many are just searching for the feeling of gender euphoria. This week, Dallas Ducar discusses issues around gender dysphoria and the need for trans-inclusive providers to take a holistic, person-based approach to care.

06. 04. 2022

•

35 min

Voices from the frontiers of health and medicine

Webová stránka